Definium Therapeutics Reports Positive Phase 3 GAD Results
NEW YORK, August 12, 2026 Definium Therapeutics, Inc. announced positive topline results from the Phase 3 Voyage study evaluating...
fast track
Advertisement
Alterity Expands ATH434 Potential in Neurodegenerative Disease
MELBOURNE, Australia and SAN FRANCISCO, USA, August 12, 2026 Alterity Therapeutics Limited announced that the U.S. Patent and Trademark...
Annexon Expands Phase 3 ARCHER II Trial in Geographic Atrophy
BRISBANE, Calif., August 12, 202 Annexon, Inc. announced the expansion of its ongoing Phase 3 ARCHER II trial evaluating...
LeonaBio Advances Lasofoxifene in Metastatic Breast Cancer
BOTHELL, Wash., August 12, 2026 LeonaBio, Inc. announced that its lead investigational therapy lasofoxifene will be featured in multiple...
Can-Fite Advances Phase III Programs With FDA and EMA Status
RAMAT GAN, Israel, August 12, 2026 Can-Fite BioPharma Ltd. announced an update on the regulatory status of its two...
Advertisements
AC Immune Receives FDA Fast Track Designation for ACI-7104 in Parkinson’s
LAUSANNE, Switzerland, August 11, 2026 AC Immune SA announced that the U.S. Food and Drug Administration (FDA) has granted...
Nicox Files NCX 470 NDA in China Through Ocumension
Sophia Antipolis, France, August 10, 2026 Nicox SA announced that its exclusive Chinese licensee Ocumension Therapeutics has submitted a...
Innate Pharma to Advance Lacutamab Toward Phase 3 with Sobi
MARSEILLE, France, August 10, 2026 Innate Pharma SA announced plans to initiate the TELLOMAK-3 confirmatory Phase 3 study of...
Scholar Rock Advances Apitegromab FDA Review with Second Fill-Finish Facility
CAMBRIDGE, Mass., August 7, 2026 Scholar Rock announced that the U.S. Food and Drug Administration (FDA) review of its...
Vedanta Biosciences Secures $60M to Advance Phase 3 VE303
CAMBRIDGE, Mass., August 6, 2026 Vedanta Biosciences announced it has secured $60 million in funding to accelerate development of...
Advertisement
